Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441577 | 0.85 | MAPK1 (0.58) | PDE2AMAPK1CFTRMRGPRX4MAPT | |
| SCHEMBL18075465 | 0.84 | PDE2A (0.60) | PDE2AMAPK1CFTRMRGPRX4MAPT | |
| SCHEMBL18097879 | 0.84 | PDE2A (0.53) | PDE2AMAPK1CFTRCYP1A2CYP2C19 | |
| SCHEMBL19914016 | 0.84 | PDE2A (0.59) | PDE2ACYP1A2CYP2C19CYP2C9KDM4E | |
| SCHEMBL18358271 | 0.83 | PDE2A (0.55) | PDE2AMAPK1CFTRMRGPRX4MAPT | |
| SCHEMBL11295277 | 0.81 | NR3C2 (0.52) | — | |
| SCHEMBL30065589 | 0.81 | NR3C2 (0.52) | — | |
| SCHEMBL30369402 | 0.80 | LMNA (0.49) | MAPTLMNA | |
| SCHEMBL4026932 | 0.80 | LMNA (0.49) | MAPTLMNA | |
| SCHEMBL18103273 | 0.79 | MAPK1 (0.43) | MAPK1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285581-B1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-01 | — | — | US | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057480-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | PDE2A 1/4885MAPK1 1235/4885CFTR 3461/4885 |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | PDE2A 1/4885MAPK1 1235/4885CFTR 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.